BioMarin, DiNAQOR to develop gene therapies for rare genetic cardiomyopathies
BioMarin Pharmaceutical has signed a preclinical collaboration and license deal with Swiss gene therapy platform company DiNAQOR to develop novel gene therapies for the treatment of rare genetic cardiomyopathies. DiNAQOR will get an undisclosed upfront payment and will stand to receive development, regulatory and commercial milestones on product sales apart from tiered royalties on global […]